Short answer
Relay Therapeutics, Inc. (RLAY) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$82M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$82M
- −10.2% YoY · +2.3% QoQ
- EPS (diluted)
- −$0.37
- +14.0% YoY · +9.8% QoQ
Source: XBRL data from the Relay Therapeutics, Inc. (RLAY) Q3 2026 10-Q on SEC EDGAR. USD.
Relay Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0 vs $0 YoY, with no product sales
- Net loss $81.7M vs $74.1M YoY, operating loss $90.2M vs $80.4M
- R&D expense $77.1M vs $68.3M, clinical-trial costs $45.2M vs $34.0M
- Cash, equivalents and investments $848.6M, operating cash outflow $169.2M through nine months
- May offering generated $296.8M net; cash expected to fund operations into 2029, with continued financing needs ahead
Risk Factors
- New regulatory risk: BIOSECURE Act enacted December 18, 2025, potentially restricting WuXi AppTec arrangements from 2027 or later
- Most material operational update: WuXi AppTec’s 1260H designation litigation, preliminary injunction granted August 7, 2026
- Clinical risk: FDA may require a companion diagnostic for zovegalisib in biomarker-defined populations
- Financial risk: $238.7 million net loss and $2.3 billion accumulated deficit as of September 30, 2026
- Funding risk: $463.0 million remaining at-the-market common-stock capacity, subject to dilution risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Relay Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.